🚨 This may be the most consequential oncology study of 2026. Yes, on par with daraxonrasib. At #ASCO26# we highlighted the 5-year KEYNOTE-942 data for the individualized mRNA cancer vaccine intismeran + pembrolizumab in resected high-risk melanoma. And the numbers were 👀 RFS HR 0.51 5-year RFS: 68.8% vs 49.1% DMFS HR 0.41 OS HR 0.47 (still immature) Amazing data. But 157 patients. Phase IIb. The big question: does it hold up in phase III? Apparently, yes. 🔥 INTerpath-001 randomized 1,137 patients with resected stage IIB-IV melanoma to intismeran + pembrolizumab vs pembrolizumab alone. At the prespecified interim analysis: ✅ RFS met ✅ DMFS met ✅ Statistically significant AND ✅ No new safety signals We don’t have the HRs yet. So some restraint until we see the actual data (also this is a press release, so grain of salt) But why is this such a big deal? Because this isn’t really about melanoma. 🧬 Sequence YOUR tumor 🎯 Identify YOUR neoantigens 💉 Manufacture a vaccine specifically for YOUR cancer 🦠 Train YOUR immune system to recognize it And now that approach has succeeded in a randomized phase III trial. This is actually personalized. And if this platform works across tumor types, the implications are enormous. Daraxonrasib may change how we treat RAS-driven cancers. INTerpath-001 may change how we think about cancer vaccines altogether. 2026 has been an amazing year for oncology advances. 🔥 @OncoAlert @Onco_Nexus @TheGutOncLab

Thrilled to share this work, now out in @JournalCancer Expert consensus statement on the use of incretin mimetics in patients with NENs, eloquently summarized by @OncoThor in the tweet below. Grateful to be a part of this effort. This statement not only provides guidance/expert advice on tackling this challenge in clinic when seeing patients but also highlights the need for robust prospective evidence to guide future use of these agents. @NANETS1 @ENETS_ORG @WinshipAtEmory

How are oncologists choosing first-line therapy for advanced HCC in an increasingly crowded treatment landscape? Learn more with @TheGutOncLab as Dr. Mark Yarchoan (@MarkYarchoan) joins Dr. Nicholas Hornstein (@GIMedOnc), Dr. Timothy Brown, MD MSCE (@TimothyJBrownMD), and Dr. Udhayvir Singh Grewal MD (@UGrewalMD), to break down the frontline treatment framework for advanced hepatocellular carcinoma, including how patient and disease characteristics influence the choice between today’s leading immunotherapy-based combinations. Watch the full episode on OncoNexus:

A randomized phase III rectal cancer trial out of China just reported some great results for Locally Advanced Rectal Cancer (and confirms our modern TNT practice). TNTCRT randomized 458 patients with high-risk LARC to conventional long-course CRT → surgery → adjuvant chemotherapy versus CAPOX before, during, and after long-course radiation. Yep. Doublet chemo, all the way through. 3-year DFS: 74.8% vs 66.0% HR 0.67 MFS: 77.7% vs 67.6% HR 0.66 pCR: 26.4% vs 9.8% Big numbers, much win. But the criticism is the comparator. The control arm is not how we treat high-risk rectal cancer in the US. We already know TNT is better than CRT → surgery → adjuvant chemotherapy based on OPRA's modern benchmark. With CRT followed by consolidation FOLFOX/CAPOX, 3-year DFS was 76%, essentially the same as the 74.8% seen here. But OPRA also comes with the added benefit of TME-free survival of 54%. I think what is still impressive is the scale and speed of this trial. The Chinese trial infrastructure is fully operational and anyone in drug development should take note. @TheGutOncLab @OncoAlert

Great experience working on this editorial. Always love when I have an opportunity to comment on the absolute magic that is Radiation Oncology. RTOG 1010 may not have been a success in the conventional sense, but the lessons learned are absolutely worth reflecting on. Thanks @NiuSanford @UGrewalMD and @TimothyJBrownMD ! @TheGutOncLab @Onco_Nexus @OncoAlert

Congrats to @TimothyJBrownMD for leading this insightful editorial on “Patient-reported outcomes and targeted therapeutic escalation in NRG Oncology/RTOG 1010: When intensification fails to translate to improved outcomes” published in @JournalCancer

Busy week for @TheGutOncLab with another new podcast episode dropping with @MarkYarchoan on to discuss systemic therapies in HCC. Check it out here @Onco_Nexus or in the next few days on Apple & Spotify @GIMedOnc @UGrewalMD

How has systemic therapy changed the role of TACE in intermediate-stage HCC? In this episode from @TheGutOncLab , Dr. Mark Yarchoan (@MarkYarchoan) joins Drs. Nicholas Hornstein (@GIMedOnc), Timothy Brown, MD MSCE (@TimothyJBrownMD), & Udhay Singh Grewal, MD (@UGrewalMD) to discuss the evolving role of TACE alongside systemic therapy in HCC and what recent combination data may mean for treatment selection and sequencing. As immunotherapy-based regimens move earlier in the treatment landscape, the group explores where TACE still fits, which patients may benefit most from a combined approach, and how practice could continue to evolve. Watch the full discussion on Oncology Nexus:

In our “Partners in Practice” series - we get a chance to hear from our other team members along w/our treating physicians. With @TimothyJBrownMD & #HeatherKline#, we 🗣️ the evolving treatment landscape of #PancreaticCancer# ⭐️ ⭐️ “Oncology Brothers” 🎙️

Clinical trials are among the most opaque parts of modern medicine. They can be dense and difficult to understand for clinicians, let alone patients. So, @TheGutOncLab recorded an episode designed to make clinical trials a little more approachable. Not just what they are, but how patients can find, evaluate, and enroll in them. This episode is geared more toward patients than clinicians, but we hope it is helpful for anyone looking for an entry point into the world of clinical trials. Video Below: Spotify: @OncoAlert @Onco_Nexus @oncodaily @cancerGRACE

Hear me out. On paper COMMIT is a "Positive" trial. It is also a spectacular demonstration that Atezolizumab monotherapy should never be used for metastatic MSI-H CRC (we can talk about adjuvant). COMMIT was a randomized first-line study in metastatic MSI-H/dMMR CRC. It began as a 3-arm trial of: • mFOLFOX6/bevacizumab (this sucks) • atezolizumab alone • mFOLFOX6/bevacizumab/atezolizumab After KEYNOTE-177 changed the standard of care, the chemotherapy-only arm closed after 20 patients. The trial continued with 82 patients randomized between atezo alone and the four-drug combination. The headline is that adding FOLFOX/bevacizumab to atezo improved PFS: HR 0.42 Median PFS: 24.5 vs 5.3 months ORR: 86% vs 46% Primary progression: 2.8% vs 32.4% The truth is Atezolizumab PALES in comparison to its contemporary PD1/PDL1 agents in this setting. Single-agent atezo: 12-month PFS 35% 24-month PFS 32% For comparison: Pembrolizumab in KEYNOTE-177: 12-month PFS 55% 24-month PFS 48% Nivolumab in CheckMate 8HW: 12-month PFS 63% 24-month PFS 56% This is not evidence that every patient with metastatic MSI-H CRC needs chemotherapy, bevacizumab, and immunotherapy. It is evidence that NO ONE SHOULD BE USING ATEZOLIZUMAB IN METASTATIC MSI-H CRC. And now, drumroll please… The only positive randomized adjuvant immunotherapy strategy in stage III dMMR colon cancer is ATOMIC: FOLFOX + atezolizumab. That makes COMMIT more than a roast. It raises a important question about ATOMIC. Should we be using Atezolizumab in the adjuvant setting? Do we need to be giving chemotherapy here? Looking forward to what others make of this but this is the real question. @TheGutOncLab @OncoAlert @oncodaily

New episode of @TheGutOncLab . With a twist: we got a surgeon on. 🔪 Dr. Robert Martin joined @TimothyJBrownMD and me to talk colorectal cancer liver metastases. CRLM is one of the few spaces in metastatic GI oncology where “curable” is still on the table. But the window is narrow, and biology matters. A few highlights: 🔪 The question is not just “can we remove it?” but “how and what should we remove it?” 🩸 ctDNA is getting hard to ignore, but it should not automatically mean “more chemo forever.” Repeat it. Watch the kinetics. Get the right imaging. Discuss as a team. Surgery with biology-first thinking. New episode out now with Dr. Robert Martin, @TimothyJBrownMD, and me. OncoNexus (Out Now): Spotify (To Be Posted 7/27): Apple (To Be Posted 7/27): @UGrewalMD @OncoAlert @Onco_Nexus

This is the daraxonrasib news I’ve been refreshing the RevMed site for! The NDA has been accepted for FDA review. And before anyone says it: no, this is not “late.” NDA packets are enormous. Clinical data, CMC, safety, labeling, subgroup analyses, QA, regulatory back-and-forth. It takes time to package a drug for FDA review, especially when the goal is not “nice phase 1 signal” but actual approval. Now the timer starts. ⏱️ Why does this matter? An oral RAS inhibitor with phase 3 PFS and OS benefit is a big deal. I think we've all said that enough by now. Now the FDA gets to do what it has said it wants to do: Get life-saving drugs into patients’ hands as quickly as possible (outside of an EAP program). FDA clock officially started. ⏱️ @TheGutOncLab @OncoAlert @oncodaily @Onco_Nexus

Out now in @JAMAOnc our comment “Proper Phenotyping of Pancreatic Cancer in Database Research” in response to “Development and validation of a parsimonious risk stratification model for pancreatic cancer.” @TheGutOncLab

How often does a company stop an actively enrolling global phase III trial and open an entirely new registration study? Well, it happened last week. Agenus is moving from BATTMAN to ROBBIN (which certainly has some ethical implications for starting/stopping a study I won't comment on). BATTMAN was testing BOT/BAL against best supportive care in refractory MSS metastatic colorectal cancer. An important question, but a best supportive care control was never likely to gain traction in the United States. ROBBIN moves BOT/BAL where it may have its best chance to work: previously untreated, high-risk stage II/III MSS colon cancer, before surgery and while the primary tumor remains intact. The rationale borrows from FOxTROT and builds on early neoadjuvant immunotherapy work from MSK and others like @pashtoonkasi . The early BOT/BAL data are compelling: • Pathologic response in approximately 60–70% • Major pathologic response in ~35–40% • pCR in ~30% Those are extraordinary numbers for MSS colon cancer and outperform the chemotherapy experience from FOxTROT. ROBBIN will randomize 850 patients to short-course neoadjuvant BOT/BAL followed by standard care versus standard care alone, with event-free survival as the primary endpoint. Will the pathologic responses translate into fewer recurrences? I think there is a real chance they will. The tradeoff will be toxicity. Grade 3 colitis/diarrhea occurred in 13% in one of the early cohorts, although there were no grade 4 events and almost no impact on surgical timing. So yes, you can still smell the colitis. But it may be worth it. @TheGutOncLab @Onco_Nexus @oncodaily @OncoAlert

Happy to share our invited review on "Grade progression and high-grade transformation in Neuroendocrine Neoplasms" just out in @EndoCancer. 🔗 Forever grateful to @IHC_guy for his mentorship on this and several other projects (crazy that I even know you and get to work with you). We hope that this will be a helpful guide for colleagues while dealing with this clinical challenge that I find to be incredibly hard to navigate. Thank you @NANETS1 for the nomination and co-authors @ChandrikhaC @PoHienEar @RaulSGonzalezMD @SethConcorsMD for your contribution to this work.